Revolution Medicines (RVMD) EBITDA Margin (2019 - 2023)

Revolution Medicines has reported EBITDA Margin for 5 years, with the latest figure at 24256.47% in Q4 2023.

• On a quarterly basis, EBITDA Margin fell 2385394.0% year-over-year to 24256.47% in Q4 2023; TTM through Sep 2024 was 88031.94%, a 8662217.0% decrease from a year earlier, with the FY2023 full-year figure at 4207.12%, down 347711.0% from the prior year.
• EBITDA Margin was 24256.47% for Q4 2023 at Revolution Medicines, down from 2845.11% in the prior quarter.
• The five-year high for EBITDA Margin was 79.26% in Q1 2019, with the low at 24256.47% in Q4 2023.
• Average EBITDA Margin over 5 years is 2109.23%, with a median of 402.52% recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: EBITDA Margin jumped 254813 bps in 2022, then plunged 2385394 bps in 2023.
• Over 5 years, EBITDA Margin stood at 161.85% in 2019, then plunged by 141 bps to 389.44% in 2020, then tumbled by 44 bps to 559.33% in 2021, then rose by 28 bps to 402.52% in 2022, then tumbled by 5926 bps to 24256.47% in 2023.
• The last three EBITDA Margin figures came in at 24256.47% (Q4 2023), 2845.11% (Q2 2023), and 1071.53% (Q1 2023), per Business Quant data.